NEWS & CONTENT
Where COMED's Work Becomes Public Record
Milestones, data, publications, and recognition; a running record of COMED's progress, from grant approvals to conference stages.
COMED Named Finalist for Start-Up Business of the Year at the 2026 Malta Business Awards
COMED Therapeutics has been named one of three finalists for Start-Up Business of the Year at the 2026 Malta Business Awards.
COMED Hooks Increase PI-Positive Cells by 69% in CAPAN-2 Cells
An independent study in CAPAN-2 pancreatic cancer cells found 68.7% more PI-positive objects following treatment with COMED Hooks versus matched nLNP controls.
Beyond Tumor Control: Evidence of Cell-State Reprogramming
An independent proteomic analysis of COMED’s pancreatic cancer program provides evidence of cell-state reprogramming following treatment with COMED Hooks.
Presenting Our Pancreatic Cancer Work at CRIHM’s First Stakeholders’ Meeting
COMED presents its pancreatic cancer program at Malta’s first CRIHM Stakeholders’ Meeting, alongside researchers shaping the island’s cancer research agenda.
Malaria Program Completes Computational Design Phase, Backed by Xjenza Malta
COMED completes the computational design phase of its malaria antibody program, backed by Xjenza Malta and published in the journal Gene.
Presenting First-in-Class KRAS G12V Targeting at Pancreatic Cancer Europe’s 10th Anniversary Masterclass
COMED presents first-in-class KRAS G12V targeting at Pancreatic Cancer Europe’s 10th anniversary Masterclass for healthcare professionals.
The Full Picture: In Vivo Data Confirm COMED Hooks Suppress Tumor Growth
Full in vivo data confirm COMED Hooks suppresses tumor growth in a pancreatic cancer model, with 100% survival and strong tolerability.
COMED Presents Pancreatic Cancer Research at “Research and Innovation in Health” Event
COMED’s pancreatic cancer research program was selected among leading projects to present its work, with Nezih Hekim, Nadir Gül and Cenk Öztürk representing the team.
Prof. Godfrey Grech Joins COMED Therapeutics Scientific Advisory Board
Prof. Godfrey Grech, PhD, joins COMED Therapeutics’ Scientific Advisory Board, bringing expertise in molecular genetics, oncology, and clinical translation.
COMED Presents Next-Generation Intracellular Delivery Platform at XI Malta Medical School Conference
COMED Therapeutics showcased technology designed to enable therapeutic antibodies to reach intracellular targets, contributing to scientific exchange and medical innovation in Malta.
COMED at MedTech Malta 2025: Reflections from Our CEO
Cenk Öztürk, MD reflects on the engagement of Malta’s leadership with COMED’s cancer research and the country’s growing focus on medical innovation and investment.
Preliminary In Vivo Data Show Slower Tumor Growth with COMED Hooks
Early animal-study results indicate a meaningful difference in tumor growth following treatment with COMED Hooks, alongside ongoing antibody development and preclinical work.